A CLINICAL STUDY TO EVALUATE SOTAGLIFLOZIN IN SYMPTOMATIC OBSTRUCTIVE AND NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Patients are helping shape the future of HCM Treatment
Living with hypertrophic cardiomyopathy (HCM) can affect more than just your heart; it can impact your daily life, your plans, and the people around you.
By taking part in clinical research, patients are helping advance a potential new treatment that could make a difference for people living with HCM.
The study is no longer enrolling patients
Participation has exceeded the original goal, and patients are being followed in accordance with the study protocol
Watch this video to learn what helped patients determine if the study experience might be right for them
ABOUT THIS STUDY
This clinical study is investigating sotagliflozin, a once-daily dual-action SGLT1 & SGLT2 (Sodium-Glucose Co-Transporter) inhibitor, to see if it can improve symptoms of HCM. Earlier studies suggest it may lower the risk of heart failure events, heart attacks, and strokes.1,2 Researchers are now assessing its potential benefits for people living with obstructive and non-obstructive HCM.
1. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117–128. doi:10.1056/NEJMoa2030183. 2. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129–139. doi:10.1056/NEJMoa2030186.
Why Take Part?
People take part in clinical studies for many different reasons. For some, it’s about exploring new possibilities. For others, it’s about helping future generations.
By participating in this clinical trial, patients are:
- Contributing to research that may improve future HCM treatments
- Helping deepen understanding of this condition
- Part of progress that could benefit people living with HCM
What was involved?
Study patients:
- Attend a small number of study visits and phone check-ins
- Receive either the study medication or a placebo (inactive treatment)
- Can remain on their current medical treatments, including myosin inhibitors
- Are supported and monitored by a dedicated study team
Study eligibility
Patients were eligible to participate if they had been diagnosed with HCM and met certain criteria, including:
- Are 18 years or older
- Have a stable heart condition – safe to participate in the study
- Are experiencing symptoms associated with HCM
- Have certain blood sugar levels – with or without diabetes
- Can take the study medication and attend visits
- Note: Study investigators also used other criteria to determine eligibility
Important: Study doctors reviewed each applicant’s medical history to confirm eligibility.
Sotagliflozin is an investigational drug and is not currently approved for use by regulatory agencies like the FDA – its safety and effectiveness has not been established in HCM.
Copyright © 2026, Lexicon Pharmaceuticals. All Rights Reserved